Tumor targeting properties of indium-111 labeled genetically engineered Fab' and F(ab')2 constructs of chimeric tumor necrosis treatment (chTNT)-3 antibody.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002614:Chelating Agents / Q000378:metabolism / Q000494:pharmacology; D016503:Drug Delivery Systems / Q000379:methods*; D005822:Genetic Vectors; D007140:Immunoglobulin Fab Fragments / Q000096:biosynthesis / Q000235:genetics; D007205:Indium Radioisotopes / Q000008:administration & dosage; D051379:Mice; D009369:Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D004369:Pentetic Acid / Q000494:pharmacology; D015202:Protein Engineering / Q000379:methods*; D014018:Tissue Distribution; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology*
D000911:Antibodies, Monoclonal; D002614:Chelating Agents; D007140:Immunoglobulin Fab Fragments; D007205:Indium Radioisotopes; D014409:Tumor Necrosis Factor-alpha; D004369:Pentetic Acid